---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-001226"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:46:26.067121+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Foghorn reports $243.8M cash runway into 2027; pipeline milestones for FHD-909, CBP/EP300 degraders

## Summary
- Preliminary cash, equivalents and marketable securities of $243.8M as of Dec 31, 2024; runway into 2027.
- Phase 1 trial of oral SMARCA2 inhibitor FHD-909 for SMARCA4-mutated cancers advancing; NSCLC primary target.
- Preclinical combination data for FHD-909 with pembrolizumab and KRAS inhibitors to be presented at AACR April 2025.
- Selective ARID1B degradation achieved; program update expected in 2025. ARID1B implicated in up to 5% of solid tumors.
- Selective CBP and EP300 degrader programs advancing with preclinical data showing anti-tumor activity and tolerability.

## SEC filing metadata
- accession: 0001628280-25-001226
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828025001226/0001628280-25-001226-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828025001226/fhtx-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-001226
- JSON: https://secwatch.observer/filing/0001628280-25-001226.json
- Plain text: https://secwatch.observer/filing/0001628280-25-001226.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.